Systemic Absorption and Pharmacokinetics of Five Novel Topical Dermatologic Agents: A Review

December 2025 in “ JEADV Clinical Practice ”

Mary Dyson, Kara Hurley, Hannah Chaudhury, Lara Shehadeh, Cameron West

ruxolitinib cream tirbanibulin ointment clascoterone cream minocycline foam tapinarof cream

Studysummary This review reports that innovative topical treatments for dermatologic conditions like acne and atopic dermatitis show minimal systemic absorption, indicating improved safety and tolerability compared to traditional therapies.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on onlinelibrary.wiley.com →

Discuss this study in the Community →

Research cited in this study

3 / 3 results

research Guidelines of Care for the Management of Acne Vulgaris

5 citations , January 2024 in “Journal of the American Academy of Dermatology”

This study provided 18 evidence-based recommendations for managing acne vulgaris, strongly endorsing treatments like benzoyl peroxide, topical retinoids, and oral isotretinoin for severe cases, and issued conditional recommendations for therapies like salicylic acid and spironolactone, while offering good practice statements on combining treatment methods.

A Phase 1 Study to Investigate the Effects of Cortexolone 17α-Propionate, Also Known as Clascoterone, on the QT Interval Using the Meal Effect to Demonstrate ECG Assay Sensitivity

research A Phase 1 Study to Investigate the Effects of Cortexolone 17α-Propionate, Also Known as Clascoterone, on the QT Interval Using the Meal Effect to Demonstrate ECG Assay Sensitivity

2 citations , May 2021 in “Clinical Pharmacology in Drug Development”

This phase 1 study reported that after administering supratherapeutic doses of cortexolone 17α‐propionate, a topical antiandrogen intended for hair loss treatment, there was no effect on the QTc interval, indicating no measurable cardiac safety concerns in the concentration range tested.

research Clascoterone: First Approval

27 citations , October 2020 in “Drugs”

This article reviews the development milestones of clascoterone up to its first approval for treating acne vulgaris, reporting no new clinical results for androgenetic alopecia.